This transaction will significantly strengthen CGI's position as a premier leader for oncology discovery, in vivo and in vitro drug development and early phase clinical trial testing for biotechnology and pharmaceutical companies
These have been developed for various non-malignant haematology disorders such as platelet function disorders, inherited thrombocytopenia and congenital neutropenias.